FDA opens preliminary inquiry into risks of epilepsy drugs

Share this article:

The FDA has begun an inquiry into whether epilepsy drugs may increase the risk of suicidal behavior in some patients, with a focus on those who use them for psychiatric illnesses.
The inquiry was prompted in part by a lawyer's claims against the leading anti-convulsant, Neurontin. The FDA last month asked makers of all epilepsy drugs to re-examine research to see if there was evidence of increased suicide risk.
Robert Temple, the agency's drug policy chief told the Associated Press, "I don't think we have any suspicion yet that these drugs actually do that."
The analysis is the same as what the agency ordered last year for antidepressants amid controversy over their use by children and teenagers.
Ultimately, those drugs were linked to an increase in suicidal thoughts and actions in a small fraction of young patients.

 

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.